Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Rhea-AI Summary

Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, will participate in the Cantor Global Healthcare Conference 2025. The company's presentation will take the format of a fireside chat featuring President & CEO Chris Giordano and Chief Medical Officer Dr. Stuart Rich.

The presentation is scheduled for September 4, 2025, at 10:20 a.m. ET in New York. Investors can access both the live and archived webcast through the company's investor relations webpage.

News Market Reaction – TENX

+0.17%

+0.17% Session close to close

In the Aug 28 session, TENX gained 0.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place from September 3-5, 2025, in New York, NY.

Details of presentation:

Format: Fireside chat

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer

Date and Time: September 4, 2025, at 10:20 a.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners
tenax@argotpartners.com

FAQ

When is Tenax Therapeutics (TENX) presenting at the Cantor Global Healthcare Conference 2025?

Tenax Therapeutics will present on September 4, 2025, at 10:20 a.m. ET in New York.

Who will represent Tenax Therapeutics (TENX) at the Cantor Healthcare Conference?

Chris Giordano, President & CEO, and Dr. Stuart Rich, Chief Medical Officer, will represent Tenax Therapeutics in a fireside chat format.

How can investors access the Tenax Therapeutics (TENX) presentation at the Cantor Conference?

Investors can access both the live and archived webcast of the presentation through Tenax Therapeutics' investor relations webpage.

What is Tenax Therapeutics' (TENX) current development stage?

Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies.